ERK-IN-3

CAS No. 2055597-12-9

ERK-IN-3( ASN007 free base )

Catalog No. M23920 CAS No. 2055597-12-9

ERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 121 In Stock
5MG 120 In Stock
10MG 174 In Stock
25MG 282 In Stock
50MG 452 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ERK-IN-3
  • Note
    Research use only, not for human use.
  • Brief Description
    ERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
  • Description
    ERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ASN007 free base
  • Pathway
    MAPK/ERK Signaling
  • Target
    ERK
  • Recptor
    ERK1|ERK2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2055597-12-9
  • Formula Weight
    473.93
  • Molecular Formula
    C22H25ClFN7O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL (527.50 mM; Need ultrasonic)
  • SMILES
    O=C(C1=CN(C2=NC(NC3CCOCC3)=NC=C2C)C=N1)N[C@@H](C4=CC(F)=CC(Cl)=C4)CN
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Sanjeeva PR, et, al. Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models. Molecular Cancer Therapeutics. 2018 Jan; 17(1).
molnova catalog
related products
  • AZ32

    AZ32 is an orally bioavailable and blood-brain barrier-penetrating?ATM?inhibitor with an?IC50?of <6.2 nM for ATM enzyme, and an?IC50?of 0.31 μM for ATM in cell.

  • Decursinol angelate

    Decursinol angelate has anti-tumor, anti-inflammatory, anti-oxidant, and hepatoprotective activities, it inhibits VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.

  • Byakangelicol

    Byakangelicol may inhibit P-gp expressed at the BBB even under in vivo conditions.